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Objectives: Dysregulation of trophoblast invasion into the decidual stroma and spiral arteries during
early gestation is one of the major factors associated with the pathogenesis of preeclampsia. Therefore,
the objective of this study was to evaluate, based on recent studies, the role of microRNAs (miRNAs) in
trophoblast proliferation, differentiation, invasion, and apoptosis during the early gestation of pre-
eclamptic pregnancies.
Materials and methods: This systematic review included articles between 2007 and 2015 that were
obtained from the MEDLINE database. The articles were identiﬁed by searching using a combination of
Medical Subject Headings (MeSH terms), namely “preeclampsia”, “pre-eclampsia”, “miRNA”, and
“microRNA”. All sources of miRNAs, all types of preeclampsia, and all techniques used when measuring
miRNAs were included in the reviewed papers.
Results: Conﬁrmed upregulation of miR-125b-1-3p, miR-20a, miR-29b, miR-181a, miR-16, miR-210, and
miR-155 and conﬁrmed downregulation of miR-17, miR-19b1, miR-195, miR-378a-5p, miR-376c, and
miR-675 were identiﬁed as involved in repressing the proliferation, differentiation, and invasion of
trophoblast cells. In addition, upregulation of miR-29b and downregulation of miR-378a-5p and miR-
376c were found to be associated with increased trophoblast cell apoptosis.
Conclusion: Overall, miRNAs have been conﬁrmed to be involved in the shallow invasion by trophoblasts
into the spiral arteries and decidual stroma during early gestation and these miRNAs are possible
promising biomarkers that may help to predict preeclampsia in the future.
Copyright © 2015, Buddhist Compassion Relief Tzu Chi Foundation. Published by Elsevier Taiwan LLC. All
rights reserved.1. Introduction
Preeclampsia is a disease of pregnancy characterized by the new
onset of hypertension and proteinuria after 20 weeks of gestation
[1]. Preeclampsia affects 3e5% of pregnancies and complicates
3e8% of pregnancies, which leads to a high disease burden among
pregnant women [2]. Preeclampsia causes a range of maternal
complications, including renal failure, hemolysis, elevated liver
enzymes and low platelet count (HELLP) syndrome, disseminated
intravascular coagulation, placental abruption, liver failure,ool of Medicine, Syiah Kuala
3111, Indonesia. Tel./fax: þ62
n).
elief Tzu Chi Foundation. Publishepulmonary edema, stroke, and cerebral edema with seizures [1,3].
As the placenta is involved in preeclampsia, this also increases the
possibility of fetal complications, which include low birth weight,
prematurity, intrauterine fetal growth restriction, oligohydramnios,
bronchopulmonary dysplasia, and perinatal death [1,4,5].
Although the exact etiology of preeclampsia is not clear, it is
believed that placental insufﬁciency is central to the pathogenesis
of preeclampsia [6,7]. Several pieces of evidence support this the-
ory including: (1) placenta from preeclampsia patients has been
found to have infarcts and to show sclerotic narrowing of the ar-
terioles; (2) placenta bed biopsies have identiﬁed that these sam-
ples show inadequate trophoblast invasion of the maternal
decidual arterioles, which results in tight and constricted vessels;
(3) various medical conditions involving underlying vascular
insufﬁciency, such as chronic hypertension and diabetes, or con-
ditions that decrease placental blood ﬂow, such as multipled by Elsevier Taiwan LLC. All rights reserved.
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risk of preeclampsia; (4) the creation of placenta insufﬁciency by
disrupting uterine blood ﬂow has been shown to cause
preeclampsia-like events using animal models; and (5) when pre-
eclampsia occurs in cases of extrauterine pregnancy, removal of the
fetus alone is not sufﬁcient and the symptoms persist until the
placenta is removed [6e8].
During a normal healthy pregnancy, a highly coordinated pro-
gram within the body ensures that the placenta and fetus are
provided with an adequate blood supply; this process is essential
for the provision of adequate oxygen and nutrients to the fetus.
Cytotrophoblasts originating from the fetus migrate into the
maternal vasculature and invade the maternal spiral arteries. These
invasive trophoblast cells gradually replace the endothelial lining of
these vessels and differentiate into endothelial-like cells. During
this process (invasion and differentiation), trophoblasts change the
expression of certain cytokines, various adhesion molecules, a
range of extracellular matrix molecules and various metal-
loproteinases, as well as the expression of the major histocom-
patibility complex and the histocompatibility leukocyte antigen-G
[7]. This process converts low-capacitance and high-resistance
vessels into high-capacitance and low-resistance vessels [7,9,10].
In preeclampsia, this complex and coordinated process is signiﬁ-
cantly disrupted and normal remodeling of the spiral arteries does
not occur. This results in retention in these mothers of small vessels
that retain high resistance and low-capacity [10,11]. The major
result of this lack of change is insufﬁcient blood ﬂow to the ute-
roplacental area.
MicroRNAs (miRNAs), a member of the noncoding groups of
RNAs, are involved in the speciﬁc regulation of both protein-coding
and putatively noncoding genes via post-transcriptional silencing
or, in rare cases, via gene activation [12]. miRNAs play important
roles in physiological homeostasis and health, as well as in the
pathophysiological derangements associated with various diseases
[13]. The various physiological processes that miRNAs are involved
in include the cell cycle [14], cell differentiation [15], development
[15], metabolism [16], various immune responses [17], and a
number of other processes [12]. miRNAs are also associated with
various pathophysiological conditions such as various noninfec-
tious diseases [18e20] and infectious diseases [21e24]. In terms of
pregnancy, miRNAs have been found to play pivotal roles in a
number of processes including homeostasis during the peri-
implantation period and placentation [25], embryonic stem cells
regulation [26], fetal growth restriction [27], intrauterine growth
retardation [28], small for gestational age [29], and preeclampsia
[30,31].
Since 2007, a range of studies have been conducted that have
investigated in depth the role of miRNAs in the pathogenesis of
preeclampsia. This systematic review has been conducted to eval-
uate the role of miRNAs in preeclampsia pathogenesis. The aim is to
evaluate the role(s) of miRNAs in trophoblast proliferation, differ-
entiation, invasion, and apoptosis based on recent conﬁrmed and
published research ﬁndings.
2. Materials and methods
In this systematic review, articles present in the MEDLINE
database between 2007 and 2015 were identiﬁed by searching
using the keywords: “preeclampsia”, “pre-eclampsia”, “miRNA”,
and “microRNA”. The bibliographies of the articles retrieved were
scanned for any further relevant references. All studies that
measured the presence of miRNAs in plasma, placenta material,
human umbilical vein endothelial cells (HUVECs), peripheral blood
mononuclear cells (PBMCs), and mesenchymal stem cells (MSCs)
were included. In addition, any and all techniques that can be usedto measure the expression of miRNAs, including microarray,
quantitative reverse transcription polymerase chain reaction (qRT-
PCR) and next-generation sequencing, were also included. In cases
where the study applied a microarray approach that was then
conﬁrmed by qRT-PCR, the expression levels of the miRNAs pre-
sented in this systematic review are the miRNA levels that have
been conﬁrmed by qRT-PCR.
Because miRNAs regulate several pathological processes related
to preeclampsia pathogenesis, the results of our systematic review
have been divided into two parts. The present article describes the
roles of miRNAs in trophoblast functioning, whereas the second
outlines the roles of miRNAs in angiogenesis and the control of
vascular pressure. Speciﬁcally, in this article, the role of miRNAs in
the dysregulation of trophoblast proliferation, differentiation, and
invasion, as well as their effect on apoptosis, all of which play a part
in preeclampsia pathogenesis, are discussed.
3. Results
The role of miRNA in preeclampsia pathogenesis has been
investigated intensively since 2007. The ﬁrst report was published
in 2007 and this found that the expression of two miRNAs was
signiﬁcantly higher in preeclamptic placentas than normal pla-
centas [32]. Following this novel ﬁnding, a signiﬁcant number of
further studies have been published [33e74].
In general, these studies have investigated the differential
expression of miRNAs using several sources of experimental ma-
terial, including placenta [33e36,38,40,47e51,54e57,
59e62,66,68,70e74], plasma [39,41e46,50,63e67], PBMCs [52],
HUVECs [69], and MSCs from the decidua or the umbilical cord
[37,53,58]; these samples were obtained from women who had
preeclampsia and from women undergoing a normal pregnancy.
These studies were carried out in The People's Republic of China
[33e35,37,40,42,43,45,50,52e58,63,64,67,69,72e74], the USA
[32,46e48,51,54,61,70,71], South Korea [49], Canada [50,60], Japan
[62], Turkey [65], Chile [66], Germany [68], Hungary [59],
Switzerland [36], Norway [38], Italy [39], Spain [41], and the Czech
Republic [44] (see Table 1 for details).
One of the factors causing preeclampsia is a deﬁcient tropho-
blast invasion of the placental bed spiral arterioles; this alters the
trophoblast-mediated remodeling of the spiral arteries and results
in reduced uteroplacental perfusion. It is clear that shallow
trophoblast invasion and impaired spiral arterial remodeling can be
considered to be the initial pathological step in preeclampsia. One
of the target areas of the miRNAs that forms a link with pre-
eclampsia pathogenesis is the dysregulation of trophoblast prolif-
eration, proliferation, and invasion. This occurs during early
pregnancy and leads to the development of preeclampsia. A range
of miRNAs have been conﬁrmed to play pivotal roles in this process
by targeting a number of different genes. In addition, miRNAs have
also been found to be involved in deﬁciencies in trophoblast inva-
sion that are associated with the induction of trophoblast cell
apoptosis. Both of these mechanisms have the effect of producing a
signiﬁcant reduction in uteroplacental blood ﬂow.
4. Discussion
4.1. The roles of miRNAs in trophoblast proliferation, survival and
invasion
A number of studies have found that expression of miR-125b-1-
3p in placenta samples from severe preeclampsia patients is
signiﬁcantly upregulated compared to control samples [33,35].
Further evidence has revealed that higher expression of miR-125b-
1-3p decreases the invasiveness of trophoblasts and that this occurs
Table 1
Summary of studies related to differential expression of miRNAs in preeclampsia.
Country Patients Sample &
method
Upregulation of miRNA(s) Downregulation of miRNA(s) Reference
The People's Republic of
China
13 sPE vs. 25 control Placenta
RT-qPCR
miR-1, miR-16, miR-19b, miR-20a,miR-
125b-1-3p, miR-181a, miR-182, miR-
210, miR-355, miR-424, miR-1469
miR-29a-3p, miR-200c,miR-335,miR-
363,miR-584,miR-744, miR-1826
[33]
The People's Republic of
China
115 PE vs. 115 control Placenta
RT-qPCR
d miR-126 [34]
The People's Republic of
China
13 sPE vs. 25 control Placenta
RT-qPCR
miR-125b-1-3p d [35]
Switzerland 15 sPE vs. 14 control Placenta
RT-qPCR
d miR455-3p, miR455-5p [36]
The People's Republic of
China
20 sPE and PE vs. 20 control MSC-decidual
RT-qPCR
miR-136, miR-495, miR-16, miR-29b,
miR-140-5p, miR-30a, miR-100, miR-
494, miR-221
miR-1207-5p [37]
Norway 23 PE vs. 23 control Placenta
RT-qPCR
d miR-1301, miR-223, miR-224 [38]
Italy 24 sPE vs. 24 control Plasma
TaqMan
microarray
miR-1233, miR-650, miR-520a, miR-
215, miR-210, miR-25, miR-518b, miR-
193a-3p, miR-32, miR-204, miR-296-
5p, miR-152
miR-126, miR-335, miR-144, miR-204,
miR-668, miR-376a, miR-15b
[39]
The People's Republic of
China
15 sPE vs. 26 control Placenta
RT-qPCR
miR-210 d [40]
Spain 31 PE vs. 44 control Plasma
RT-qPCR
miR-192, miR-143, miR-125b miR-127, miR-942, miR-126#, miR-221 [41]
The People's Republic of
China
9 sPE vs. 22 control Plasma
RT-qPCR
miR-155 d [42]
The People's Republic of
China
20 sPE vs. 33 control Plasma
RT-qPCR
miR-210, miR-30a-3p, miR-518b, miR-
524, miR-17-3p, miR-151, miR-193b
miR-195, miR-223, miR-218, miR-379,
miR-411, miR-17, miR-18a, miR-19b1,
miR-92a1
[43]
The People's Republic of
China
20 sPE vs. 33 control Plasma
RT-qPCR
miR-210 miR-18a, miR-19b1, miR-92a1 [43]
Czech Republic 63 PE vs. 55 controls Plasma
RT-qPCR
miR-516-5p, miR-517*, miR-520a*,
miR-525, miR-526a
d [44]
The People's Republic of
China
16 PE vs. 32 control Plasma
RT-qPCR
miR-141, miR-29a miR-144 [45]
The People's Republic of
China
22 sPE vs. 32 control Plasma
RT-qPCR
miR-141, miR-221, miR-29a d [45]
USA 33 PE vs. 34 control Plasma
RT-qPCR
miR-210 d [46]
USA 20 PE vs. 56 control Plasma
RT-qPCR
miR-210 d [46]
USA 16 PE vs. 12 control Placenta
RT-qPCR
miR-210, miR-182* d [47]
USA 19 PE vs. 40 control Placenta
RT-qPCR
d miR-149 [48]
South Korea 21 sPE vs. 20 control Placenta
RT-qPCR
miR-92b, miR-197, miR-342-3p, miR-
296-4p, miR-26b, miR-25, miR-296-3p
miR-21, miR-223 [49]
Canada 11 PE vs. 25 control Placenta
RT-qPCR
d miR-376c [50]
The People's Republic of
China
15 PE vs. 22 control Placenta
RT-qPCR
d miR-376c [50]
The People's Republic of
China
13 PE vs. 13 controls
(preterm)
Plasma
RT-qPCR
d miR-376c [50]
The People's Republic of
China
16 PE vs. 31 control Plasma
RT-qPCR
d miR-376c [50]
USA 8 PE vs. 8 control Placenta
RT-qPCR
miR-106a, miR-19b d [51]
The People's Republic of
China
12 PE vs. 12 control PBMC
qRT-PCR
d miR-126 [52]
The People's Republic of
China
20 sPE vs. 20 control MSC-decidua
qRT-PCR
miR-16 d [53]
USA 6 sPE vs. 6 control Placenta qRT-
PCR
miR-210 d [54]
The People's Republic of
China
10 sPE vs. 24 control Placenta qRT-
PCR
d miR-675 [55]
The People's Republic of
China
15 sPE vs. 17 control Placenta qRT-
PCR
d pri-miR-195, miR-195 [56]
The People's Republic of
China
24 sPE vs. 26 control Placenta
qRT-PCR
miR-29b d [57]
The People's Republic of
China
13 PE vs. 16 control MSC-decidua
qRT-PCR
miR-181 d [58]
The People's Republic of
China
11 PE vs. 16 control MSCs-umbilical
cord
qRT-PCR
miR-181 d [58]
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Table 1 (continued )
Country Patients Sample &
method
Upregulation of miRNA(s) Downregulation of miRNA(s) Reference
Hungary 31 PE 28 vs. control Placenta qRT-
PCR
d miR-325 [59]
Canada 15 PE vs. 22 control Placenta qRT-
PCR
d miR-378a-5p [60]
USA 10 sPE vs. 10 control Placenta qRT-
PCR
miR-17, miR-20a, miR-20b d [61]
Japan 8 PE vs. 10 control Placenta
qRT-PCR
miR-210, miR-193b, miR-144, miR-
193b, miR-18a, miR-185, miR-19a, miR-
590e5p, miR-142e3p, miR-451, miR-
22, miR-526b, miR-520a-3p, miR-10b,
miR-20a, miR-518f, miR-146b-5p, miR-
517c, miR-518c, miR-525e5p, miR-
519e, miR-126
miR-145, miR-143, miR-188-5p, miR-
107, miR-133a, miR-105, miR-224, miR-
551b, miR-542-5p, miR-186
[62]
The People's Republic of
China
10 sPE vs. 9 control Plasma
qRT-PCR
miR-24, miR-26a, miR-103, miR-130b,
miR-181a, miR-342-3p, miR-574-5p
d [63]
The People's Republic of
China
2 PE and 2 sPE vs. 1 control Plasma
NGS
miR-521, miR-520h, miR-517c, miR-
519d, miR-517b, miR-542-3p, miR-136,
let-7f-1, miR-125b, miR-125a-5p, miR-
519a, miR-29a
let-7f, miR-223, miR-1260, let-7d, miR-
320c, miR-185, miR-1272
[64]
Turkey 20 PE vs. 20 control Plasma
qRT-PCR
miR-210 miR-152 [65]
Chile 52 PE and 31 PE þ SGA vs.
72 control
Placenta
qRT-PCR
miR-210 d [66]
The People's Republic of
China
15 PE and 15 sPE vs. 15
controls
Plasma qRT-
PCR
miR-210 d [67]
Germany 5 sPE vs. 5 control Placenta qRT-
PCR
let-7b, miR-302*, miR-104, miR-128a,
miR-182*, miR-133b
d [68]
China 5 sPE vs. 5 control HUVEC
qRT-PCR
miR-155 [69]
USA 20 PE vs. 20 control Placenta qRT-
PCR
miR-210 miR-328, miR-584, miR-139-5p, miR-
500, miR-1247, miR-34c-5p, miR-1
[70]
USA 6 PE vs. 5 control Placenta
qRT-PCR
miR-496 miR-15b, miR-181, miR-210, miR-
483d5p
[71]
The People's Republic of
China
20 sPE vs. 20 control Placenta
qRT-PCR
miR-155 [72]
The People's Republic of
China
24 sPE vs. 26 control Placenta
qRT-PCR
miR-16, miR-29b, miR-195, miR-26b,
miR-181a, miR-335, miR-222
d [73]
The People's Republic of
China
8 PE and 15 sPE vs. 11
control
Placenta
qRT-PCR
miR-152 miR-210, miR-411, miR-377 [74]
The People's Republic of
China
15 sPE vs. 11 control Placenta
qRT-PCR
miR-210, miR-152, miR-518b miR-411, miR-377, miR-18a, miR-363,
miR-542-3p
[74]
USA 9 PE vs. 9 spontaneous
preterm labor
Placenta
qRT-PCR
miR-182, miR-210 d [32]
USA 9 PE þ SGA vs. 9
spontaneous preterm labor
Placenta
qRT-PCR
miR-210, miR-155, miR-181b, miR-
182*, miR-200b, miR-154*, miR-183
d [32]
HUVEC ¼ human umbilical vein endothelial cell; MSC ¼ mesenchymal stem cells; NGS ¼ next-generation sequencing; PBMC ¼ peripheral blood mononuclear cell;
PE ¼ preeclampsia; qRT-PCR ¼ quantitative reverse transcription polymerase chain reaction; SGA ¼ small for gestational age; sPE ¼ severe preeclampsia.
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(S1PR1) [35]. S1PR1 is a G-protein-coupled receptor of sphingo-
sine-1-phosphate and this protein plays a critical role in angio-
genesis inhibition and the maintenance of vascular stability. An
earlier study has revealed that activation of S1PR1 is able to pro-
mote the invasion of trophoblast cells [75]. Therefore, it is clear that
the trophoblast invasion-inhibiting effect of miR-125b-1-3p occurs
via a suppression of S1PR1 expression (Fig. 1).
Other studies have found that a downregulation of miR-18a
occurs in severe preeclamptic placenta samples [43,74]. However,
one study did ﬁnd that the expression of miR-18a is upregulated in
mild preeclamptic placenta samples [62]. Using a human tropho-
blast cell line, miR-18a was found to promote trophoblast invasion
by targeting and suppressing Smad2 expression (Fig. 1) [43]. Smad
proteins are able to modulate signaling using transforming growth
factor b (TGF-b) and they play a major role as the central mediators
of TGF-b signaling. The modulation by miR-18a of the TGF-b
signaling pathway thus plays an essential role in the regulation of
trophoblast cell activity. Other studies have found that the mem-
bers of miR-17-92 cluster (miR-17, miR-19b1) are downregulated insevere preeclamptic placenta samples [43]. It has been found that
miR-17 and miR-19b1 target Smad6/Smad7 and Smad4/Smad5,
respectively (Fig. 1). However, one study by Wang et al [61] dis-
agrees with the above ﬁndings. This investigation found that there
was upregulation of miR-17 expression in severe preeclamptic
placenta samples.
A number of studies have found that miR-20a is upregulated in
preeclamptic placenta samples [33,61,62] and that this miRNA
directly targets the forkhead box protein (FOX)A1 [76]. FOXA1, a
member of the FOX family of transcription factors, plays key roles in
cell proliferation and migration during organ development [77].
One study using an in vitro model found that overexpression of
miR-20a signiﬁcantly inhibited the proliferation, migration, and
invasion of a trophoblast-like cell line and that this occurred by
direct regulation of FOXA1 (Fig. 1) [76].
One of the other miRNAs found to be involved in trophoblast
proliferation, proliferation, and invasion is miR-29b. Studies have
conﬁrmed that expression of miR-29b is upregulated in placenta
samples from severe preeclampsia patients [45,73] and in MSCs
from the decidual tissue [37] from severe preeclampsia patients.
H. Harapan, M. Andalas / Tzu Chi Medical Journal 27 (2015) 54e6458Speciﬁcally, Li et al. [45] found that increased expression of miR-
29b is able to inhibit the invasion of trophoblasts and decreased
network formation and the number of capillary tubes. They also
demonstrated that miR-29b overexpression reduced trophoblast
invasiveness [45]. A number of different mechanisms have been
suggested as being involved in this effect of miR-29. Trophoblast
invasiveness is known to depend on the production of matrix
metalloproteinase-2 (MMP2), and during invasion, trophoblast
cells have also been shown to express various integrins, including
integrin beta 1 (ITGB1). One study found that miR-29b targets
MMP2 and ITGB1 directly [45]. Interestingly, this ﬁnding is sup-
ported by the fact that the messenger RNA levels of MMP2 and
ITGB1 are lower in preeclamptic placenta samples [45]. In addition,
miR-29b has also been found to induce the dysregulation of
signaling in trophoblast cells via the involvement of extracellular
signal-regulated kinase (ERK) and focal adhesion kinase (FAK) [45].
ERK/FAK signaling is one of the most important signaling pathways
controlling the expression of the growth factors that are involved in
migration and the invasion of trophoblasts. Taking these ﬁndings
together, they indicate that overexpression of miR-29b in pre-
eclampsia would seem to cause dysregulation of ERK/FAK signaling
pathways and this is able to suppress MMP2 and ITGb1 production
(Fig. 2). However, how miR-29b represses ERK/FAK signaling re-
mains unknown.
Although an early study found that miR-195 is upregulated in
severe preeclamptic placenta samples [73], a recent study has
found that the expression of miR-195 is downregulated in both
plasma [43] and placenta [56] samples from severe preeclampsia
patients. A study conducted by Bai et al [56] found that down-
regulation of miR-195 is correlated with upregulation of activin A
receptor type IIA (ActRIIA) in severe preeclamptic placenta samples
compared to normal placenta samples. ActRIIA (also known as
Acvr2a) is a receptor for activin A and Nodal. Both of these mole-
cules (activin A and Nodal) play central roles in activin/Nodal
signaling, a signaling system that controls the growth and differ-
entiation of trophoblasts. miR-195 has a trophoblast invasion-Fig. 1. A proposed scheme showing how miR-125b-1-3p, miR-20a, and the members of
differentiation, and invasion. Speciﬁcally, miR-125b-1-3p decreases trophoblast invasivenes
miR-20a targets FOXA1, a transcription factor that has a key role in trophoblast proliferatio
various Smad proteins. Smad proteins are important mediators that are involved in the TG
trophoblast growth during early gestation. The red arrows (downregulation) and green arr
miRNAs or indicated molecules during preeclampsia. FOXA1 ¼ forkhead box protein A1; S1
interpretation of the references to colour in this ﬁgure legend, the reader is referred to thepromoting effect that occurs via the suppression of ActRIIA
expression, which is a molecule that is important for Nodal
signaling. It has also been shown that Nodal inhibits trophoblast
cell invasion, whereas activin A promotes trophoblast cell invasion
[56]. A previous study also revealed that an upregulation of Nodal
expression occurs in preeclamptic placenta samples [78] and that it
is this promotion of Nodal signaling that induced trophoblast
apoptosis [79]. Therefore, it is clear that the increase in ActRIIA
receptor expression caused by lowered levels of miR-195 brings
about an augmentation of Nodal signaling, which in turn inhibits
trophoblast invasion (Fig. 2).
Related to Nodal signaling and trophoblast regulation, another
study found that miR-378a-5p is downregulated in preeclampsia
and that the reduced miR-378a-5p expression leads to reduced
trophoblast migration and invasion [60]. This effect is achieved via
the targeting of the Nodal protein. Downregulation of miR-378a-5p
increases Nodal expression, which in turn inhibits trophoblast
migration and invasion. Again, Nodal is a member of the TGF-b
superfamily and through activin receptor-like kinase 7 (ALK7),
which is a receptor for Nodal, inhibits trophoblast cell proliferation,
migration, and invasion, leading to trophoblast apoptosis [78].
In addition to the above, another miRNA, miR-376c, has also
been found to be involved in trophoblast proliferation, migration,
and invasion via an induction of Nodal signaling. Fu et al [50] found
that miR-376c is downregulated in preeclamptic placenta samples
and that this targets ALK7 and ALK5, which are molecules impor-
tant to the Nodal signaling pathway. The study also conﬁrmed that
Nodal and ALK7 levels are upregulated in preeclamptic placenta
samples [50]. Therefore, downregulation of miR-376c in the pre-
eclamptic placenta results in higher ALK7 expression and this then
results in the enhancement of Nodal signaling (Fig. 2).
It has also been found, in relation to Nodal signaling that
downregulation of miR-675 occurs in preeclamptic placenta sam-
ples compared to normal placenta samples and that miR-675
directly targets expression of the nodal modulator 1 (NOMO1)
protein [55]. This study also found that the level of NOMO1 isthe miR-17-92 cluster (miR-17, miR-18a, miR-19b1) reduce trophoblast proliferation,
s by targeting S1PR1, a molecule that promotes the invasion of trophoblast cell, while
n and migration. The miR-17-92 cluster members suppress and reduce expression of
F-b signaling pathway, one of the most important signaling pathways associated with
ows (upregulation) indicate the conﬁrmed changes in expression levels of the various
PR1 ¼ sphingosine-1-phosphate receptor 1; TGFb ¼ transforming growth factor b. (For
web version of this article.)
Fig. 2. A proposed mechanism model showing how miRNAs regulate trophoblast proliferation, differentiation, and invasion. Several miRNAs (miR-378-a-5p, miR-195, miRNA-376c,
and miR-675) target and interact with molecules upstream of the Nodal signaling pathway. As a result, they increase Nodal signaling, a signal cascade system that inhibits pro-
liferation, differentiation, and invasion of trophoblast cells. Speciﬁcally, miR-29b inhibits trophoblast function during early pregnancy by dysregulation of ERK/FAK signaling and
inhibition of the expression of MMP2 and ITGB1 on the trophoblast cells surface. miR-181a and miR-16 dysregulate the TGF-b and VEGF signaling pathways, respectively. Both of
these signaling pathways are important to trophoblast cell growth during placenta development. The red arrows (downregulation) and green arrows (upregulation) indicate the
conﬁrmed changes in the expression levels of the miRNAs or indicated molecules during preeclampsia. ActRIIA ¼ activin A receptor type IIA; ALK7 ¼ activin receptor-like kinase 7;
ERK ¼ extracellular signal-regulated kinase; FAK ¼ focal adhesion kinase; ITGB1 ¼ integrin beta 1; MMP2 ¼ matrix metalloproteinase-2; NOMO1 ¼ nodal modulator 1;
TGFBR1 ¼ TGF-b receptor 1; TGFBRAP1 ¼ TGF-b receptor associated protein 1; TGFb ¼ transforming growth factor b, VEGF ¼ vascular endothelial growth factor A. (For inter-
pretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
H. Harapan, M. Andalas / Tzu Chi Medical Journal 27 (2015) 54e64 59higher in preeclamptic placenta samples compared to normal
placenta samples. NOMO1, a highly conserved transmembrane
protein, is known to be involved in the Nodal signaling pathway.
Although a previous study in zebraﬁsh found NOMO1 to be a Nodal
signaling antagonist [80], a recent study clearly demonstrated that
silencing of the NOMO1 gene inhibits the expression of a variety of
Nodal signaling pathway-related genes in P19 cells [33]. This result
indicates that NOMO1 is important to Nodal signaling. Therefore, it
would seem that the downregulation of miR-675 in preeclampsia
patient samples increases the level of NOMO1, which in turn en-
hances Nodal signaling (Fig. 2). This then affects trophoblast pro-
liferation, differentiation, and invasion.
Another miRNA that has an important role in trophoblast in-
vasion is miR-181a. Studies have found that the expression of miR-
181a is upregulated in plasma [63] and placenta [33,73] samples
from severe preeclampsia patients as well as in MSCs derived from
the umbilical cord and decidua of preeclampsia patients [58]. Liu
et al [58] demonstrated that overexpression of miR-181a results in
a downregulation of the mRNA and protein expression of TGF-b
receptor 1 (TGFBR1) and TGF-b receptor associated protein 1
(TGFBRAP1); therefore, higher levels of miR0181a will block acti-
vation of the TGF-b signaling pathway (Fig. 2). Both TGFBR1 and
TGFBRAP1 are direct targets of miR-181a. In turn, TGF-b signaling
affects a wide range of cellular processes, including proliferation,
migration, differentiation, and apoptosis. Therefore, upregulation
of miR-181a in preeclampsia decreases TGF-b signaling and this
should lead to dysregulation of trophoblast proliferation, migra-
tion, and invasion. Apart from TGF-b, another study found that
vascular endothelial growth factor A (VEGF-A) was involved in
trophoblast migration, in tube formation, and in network formation
(angiogenesis); furthermore, it was identiﬁed that VEGF-Awas one
of the targets of miR-16 [53]. Studies of severe preeclampsia
pregnancies have consistently found that the expression of miR-16
is upregulated in placenta samples [33,73] and in the MSCs ofdecidual tissue [37,53]. Wang et al. [53] conﬁrmed that over-
expression of miR-16 is able to reduce the protein levels of VEGF-A
in preeclampsia samples.
Several studies have revealed that expression of miR-210
increased in preeclampsia patients and upregulation of miR-210
affects trophoblast migration and invasion
[32,33,39,40,43,46,54,63,65e67,71]. It is generally accepted that
expressions of various miRNAs, including miR-210, are able to be
upregulated by activation of Toll-like receptor (TLR), which includes
activation of variousTLR3 downstream pathways, such as via
hypoxia-inducible factor 1a and via tumor necrosis factor a (TNF-a)
(Fig. 3). These ﬁndings are also supported by an animal model study
[81]. Taken together, these ﬁndings indicate that miR-210 is likely
to contribute to preeclampsia pathogenesis via several different
regulatory mechanisms.
Firstly, miR-210 targets signal transducer and activator of tran-
scription 6 (STAT6). STAT6 plays a central role in interleukin-4 (IL-
4)-mediated biological responses, including being responsible for
the antiapoptotic activity of IL-4. One study found that upregula-
tion of miR-210 decreases STAT6/IL-4 and these changes may
contribute to the inﬂammatory state that is evident in preeclampsia
patients; this state may partly contribute to the development of
preeclampsia (Fig. 3) [81]. IL-4 is regulated by STAT6 and increases
during a normotensive pregnancy [81]. However, in a preeclampsia
pregnancy, the levels of IL-10 are signiﬁcantly lower than those of a
normal pregnancy [82]. In addition, one study using a preeclampsia
mouse model found that the level of IL-4 failed to increase when
the serum of preeclampsia mice was examined [83].
Secondly, miR-210 overexpression is able to reduce trophoblast
invasion in an ERK and mitogen-activated protein kinase (MAPK)
dependent manner [46]. The MAPK pathway is known to partici-
pate in trophoblast invasion during normal pregnancies and the
ERK signaling pathway is important to the regulation of
inﬂammation-associated trophoblast invasion [46]. Therefore, by
H. Harapan, M. Andalas / Tzu Chi Medical Journal 27 (2015) 54e6460targeting a molecule upstream of these signaling pathways, miR-
210 is able to inhibit trophoblast cell invasion during preeclamp-
sia (Fig. 3). The exact molecule remains unknown; however, Anton
et al [46] suggest that miR-210may function upstream of the MAPK
signaling pathway.
Thirdly, a previous study has indicated the involvement of miR-
210 in the shallow trophoblast invasion of the preeclamptic
placenta and that this occurs via targeting potassium (Kþ) channel
modulatory factor 1 gene (KCMF1) (Fig. 3) [40]. KCMF1 enhances
the proliferation, migration, and invasion of epithelial cancers
[84]. A study has found that KCMF1 expression is signiﬁcantly
lower in the placenta of preeclampsia women compared to the
normal placenta of normal women and that these levels are
inversely correlated with the level of miR-210 [40]. Luo et al. [40]
speculated that the miR-210eKCMF1 pathway is involved in im-
mune maladaptation at the fetalematernal interface during early
gestation.
Fourthly, studies have revealed that miR-210 targets Ephrin-A3
(EFNA3) (Fig. 3) [67,85]. EFNA3 is a member of the ephrin ligand
family and functions during the development of diverse organ
systems being involved in cell migration. EFNA1 expression is
limited to the invasive trophoblast lineage during pregnancy and
therefore this receptor ligand systemwould seem to be responsible
for interstitial invasion and endovascular invasion during placen-
tation [67].
Lastly, miR-210 also targets genes that are crucial to the cell
cycle, such as E2F transcription factor, ﬁbroblast growth factor
receptor-like protein, and homeobox A1 protein and such targeting
results in an inhibition of cell growth [40]. Therefore, it is clear thatFig. 3. A proposed mechanismmodel of miR-210 regulation of trophoblast growth. Speciﬁca
various molecule targets including STAT6, KCMF1, EFNA3, E2F, FGFR-like protein, and home
pathways. The red arrows (downregulation) and the green arrows (upregulation) indicate th
preeclampsia. EFNA3 ¼ ephrin-A3; ERK ¼ extracellular signal-regulated kinase; FGFR ¼ ﬁbr
4; KCMF1 ¼ potassium channel modulatory factor 1; MAPK ¼mitogen-activated protein kin
factor a. (For interpretation of the references to colour in this ﬁgure legend, the reader is rmiR-210, by targeting several essential biology molecules, is able to
repress trophoblast proliferation, migration, and invasion. As a
consequence, these effects will lead to abnormal placenta devel-
opment, which is the major causal factor of preeclampsia.
Another miRNA that is consistently overexpressed in pre-
eclampsia is miR-155 [32,42,69,72] and studies have indicated that
miR-155 is important to the regulation of trophoblast invasion
[72,86]. miR-155, a common target of a large range of inﬂammatory
mediators, is able to be upregulated by a range of inﬂammatory
factors including interferon b, lipopolysaccharide, TNF-a, and IL-1b;
this occurs via the TLR [87].
The role of miR-155 in trophoblast proliferation, differentiation,
and invasion involves targeting of at least three main molecules
(Fig. 4). One study found that miR-155 is able to directly target
cyclin D1 and that overexpression of miR-155 reduces the level of
cyclin D1 protein [86]. Cyclin D1, by facilitating the activation of
E2F-responsive genes, is important during cell growth, which in-
cludes the promotion of cell migration and the decreasing of cell
adhesion. Cyclin D1 is expressed in cytotrophoblast and extra-
villous trophoblast cells in the placenta during normal pregnancy.
One study has found that the level of cyclin D1 is reduced in pre-
eclamptic placentas [88]. These ﬁndings indicate that cyclin D1 has
important roles to play in the regulation of trophoblast prolifera-
tion and migration. In addition, cyclin D1 also interacts with p27, a
cyclin-dependent kinase inhibitor that plays an important role in
the regulation G1/S progression. Speciﬁcally, p27 is a cell cycle in-
hibitor protein. Interestingly, overexpression of miR-155, a condi-
tion that is found in preeclampsia, causes a decrease in cyclin D1
expression and an increase of p27 expression; this subsequentlylly, miR-210 inhibits trophoblast proliferation, differentiation, and invasion by inhibiting
obox A1 protein. In addition, miR-210 also dysregulates the ERK and MAPK signaling
e conﬁrmed changes in expression level of the miRNAs or indicated molecules during
oblast growth factor receptor; HIF-1a ¼ hypoxia-inducible factor 1a; IL-4 ¼ interleukin
ase; STAT6 ¼ signal transducer and activator of transcription 6; TNF-a ¼ tumor necrosis
eferred to the web version of this article.)
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proliferation (Fig. 4).
Furthermore, another study found that the role of miR-155 in
trophoblast proliferation, invasion, and migration is achieved via
the targeting of the cysteine-rich angiogenic inducer 61 (CYR61)
gene and the VEGF gene [72]. CYR61 is strongly expressed in the
placenta during normal pregnancy and is involved in angiogenesis
as well as the migration properties of trophoblast cells during
placentation. VEGF is pro-angiogenesis factor that is essential for
trophoblast invasion. In addition, VEGF is also essential for endo-
thelial cells stabilization, angiogenesis, and the control of vascular
pressure [89]. A study has conﬁrmed that overexpression of miR-
155 brings about a downregulation of CYR61 and VEGF and that
this interferes with trophoblast migration [72].4.2. The roles of miRNAs on trophoblast apoptosis
In addition to the inhibition of trophoblast proliferation, dif-
ferentiation, and migration, miRNAs are also able to interfere with
placenta development by inducing trophoblast apoptosis. For
example, overexpression of miR-29b promotes trophoblast
apoptosis by targeting myeloid cell leukemia 1 (MCL1) [45],
whereas downregulation of miR-378a-5p [60] and miR-376c [50]Fig. 4. A proposed mechanism model of miR-155 regulation of trophoblast proliferation, d
vasion, and migration mainly by suppressing the expression of cyclin D1, VEGF-A, and CYR61.
in the angiogenesis and migration properties of trophoblast cells during placentation when
(upregulation) indicate the conﬁrmed changes in expression level of the miRNAs or indica
1b ¼ interleukin 1b; LPS ¼ lipopolysaccharide; p27 ¼ atypical tumor suppressor that regu
endothelial growth factor A. (For interpretation of the references to colour in this ﬁgure lepromotes trophoblast apoptosis via regulation of the Nodal
signaling pathway.
Studies have found higher levels of expression of miR-29b in
decidual MSCs [37] and placenta samples [57,73] obtained from
women with preeclampsia, when these are compared to similar
samples obtained from women undergoing a normal pregnancy.
Furthermore, overexpression of miR-29b has been shown to pro-
mote the apoptosis of trophoblast cells and this occurs via the
downregulation of MCL1 expression, an antiapoptotic member of
the Bcl-2 family (Fig. 5). Another study conﬁrmed that the level of
expression of MCL1 mRNA is lower in preeclamptic placenta
compared with control placenta [45].
A study by Luo et al [60] found that miR-378a-5p is down-
regulated in placenta from women undergoing a preeclampsia
pregnancy and this reduction in miR-378a-5p expression leads to
excessive apoptosis of trophoblast cells, thereby contributing to
preeclampsia. Another study found that miR-378a-5p is able to
target Nodal, and the effect of miR-378a-5p on trophoblast
apoptosis is partially mediated by an increase in Nodal signaling
(Fig. 5) [78].
Finally, Fu et al. [50] found anmiRNA that seemed to be involved
in trophoblast apoptosis; this was miR-376c and this miRNA is
downregulated in both the placenta and plasma from preeclampsia
patients. Furthermore, there is a positive association withifferentiation and invasion. Speciﬁcally, miR-210 inhibits trophoblast proliferation, in-
Cyclin D1 is important to the trophoblast cell cycle, while CYR61 and VEGF are involved
there is a normal pregnancy. The red arrows (downregulation) and the green arrows
ted molecules during preeclampsia. CYR61 ¼ cysteine-rich angiogenic inducer 61; IL-
lates G0 to S phase transitions; TNF-a ¼ tumor necrosis factor a; VEGF-A ¼ vascular
gend, the reader is referred to the web version of this article.)
Fig. 5. A proposedmechanismmodel involving miR-29b, miR-378a-5p, and miR-376c showing how they affect the induction of trophoblast apoptosis. miR-29b targets antiapoptotic
MCL1,which leads to increased trophoblast apoptosis directly. Furthermore,miR-378a-5p andmiR-376c increase trophoblast apoptosis byupregulating theNodal signaling pathway, an
important signaling for trophoblast apoptosis. The red arrows (downregulation) and the green arrows (upregulation) indicate the conﬁrmed changes in expression level of themiRNAs
or indicatedmolecules during preeclampsia. ALK7¼ activin receptor-like kinase 7 (a receptor for Nodal);MCL1¼myeloid cell leukemia 1. (For interpretation of the references to colour
in this ﬁgure legend, the reader is referred to the web version of this article.)
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gene, which is important to Nodal signaling (Fig. 5). Down-
regulation of miR-376c in the preeclamptic placenta results in
higher levels of ALK7 and this enhances Nodal signaling. The
elevation in Nodal signaling in the preeclamptic placenta then in-
duces excessive apoptosis [50,79].5. Conclusion
Dysregulation of trophoblast proliferation, differentiation, and
invasion during early pregnancy is one of the major ways that
pathogenesis occurs during preeclampsia. Several miRNAs have
been conﬁrmed to be involved in this process. Overexpression of
miR-125b-1-3p, miR-20a, miR-29b, miR-181a, miR-16, miR-210,
and miR-155 together with downregulation of miR-17, miR-19b1,
miR-195, miR-378a-5p, miR-376c, and miR-675 have been
conﬁrmed in plasma and/or placenta from preeclampsia pregnancy
patients. Both of these changes repress the proliferation, differen-
tiation, and invasion of trophoblast cells. In addition, the upregu-
lation of miR-29b and the downregulation of miR-378a-5p and
miR-376c have been shown to increase trophoblast cell apoptosis.
To achieve this, these miRNAs dysregulate TGF-b and VEGF, as well
as the Nodal, MAPK, ERK, and FAK signaling pathways and these
changes interfere with the expression of various integrin mole-
cules, a number of invasiveness enzymes such as MMP2, various
transcription factors (E2F, FOXA1), a number of cell cycle regulators
(cyclin D1, p27), various angiogenic inducers (CYR61), and a range
of antiapoptotic proteins (MCL1).Acknowledgments
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